Parexel Supports Manufacturers With COVID-19 Risk Mitigation Offering
Published on:
Applied Clinical Trials
Parexel has unveiled its COVID-19 Risk Mitigation offering, so that manufacturers can safely and confidently continue operations through the COVID-19 pandemic. Parexel’s regulatory experts will partner with life sciences companies aiming to ensure business continuity during these challenging times by analyzing manufacturing operations to reduce the risk of viral contamination. This will be accomplished through a four-step methodology.
